SPOTLIGHT: Big Pharma's biotech shift hurts chemists

2007 may be remembered as the year Big Pharma moved away from chemical-based drugs and fully embraced the biologics revolution. AstraZeneca, Sanofi, and (most notably) Pfizer--among many others--have announced initiatives that involve boosting investment in biotech drugs. But with chemical-based drugs out of vogue, there's a group that's been forced to go job-hunting: chemists. Report

Suggested Articles

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.

After Merck and Bayer's vericiguat scored in a heart failure trial, you'd expect potential rivals to brace themselves. Not so for Novartis'…